# Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

> **NCT05327127** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Kowa Research Institute, Inc.** · enrollment: 228 (actual)

## Conditions studied

- NASH

## Interventions

- **DRUG:** K-877-ER
- **DRUG:** CSG452
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05327127
- **Lead sponsor:** Kowa Research Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-14
- **Primary completion:** 2026-05-05
- **Final completion:** 2026-06-02
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05327127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05327127, "Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05327127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*